Affordable Access

deepdyve-link
Publisher Website

Intravitreal Bevacizumab for Nonsubfoveal Choroidal Neovascularization Associated With Angioid Streaks

Authors
  • Battaglia Parodi, Maurizio
  • Iacono, Pierluigi
  • La Spina, Carlo
  • Berchicci, Luigi
  • Scotti, Fabrizio
  • Leys, Anita
  • Introini, Ugo
  • Bandello, Francesco1, 2, 3, 4, 5, 1, 6, 1, 7, 1, 8
  • 1 Department of Ophthalmology
  • 2 University Vita-Salute
  • 3 Scientific Institute San Raffaele
  • 4 Fondazione G. B. Bietti per l’Oftalmologia
  • 5 IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico)
  • 6 Humanitas Clinical and Research Center
  • 7 Humanitas Gavazzeni
  • 8 University Hospitals
Type
Published Article
Journal
American Journal of Ophthalmology
Publisher
Elsevier
Publication Date
Jan 01, 2014
Accepted Date
Oct 23, 2013
Volume
157
Issue
2
Pages
374–377
Identifiers
DOI: 10.1016/j.ajo.2013.10.015
Source
Elsevier
License
Unknown

Abstract

PurposeTo evaluate the effects of intravitreal bevacizumab injections in the treatment of nonsubfoveal choroidal neovascularization (CNV) associated with angioid streaks. DesignNonrandomized, interventional, prospective case series. MethodsFifteen patients (15 eyes) affected by juxtafoveal or extrafoveal CNV secondary to angioid streaks were enrolled in the study. All patients underwent a complete ophthalmologic examination, including best-corrected visual acuity (BCVA) measurement on Early Treatment Diabetic Retinopathy Study (ETDRS) chart, optical coherence tomography (OCT), and fluorescein angiography (FA). The protocol treatment included a first injection, followed by repeated injections over a 12-month follow-up period on the basis of the detection of new hemorrhage on biomicroscopic examination, any type of fluid on OCT, or presence of leakage on FA. Primary outcome measures: Mean changes in BCVA and proportion of eyes gaining at least 10 letters (2 ETDRS lines) at the end of the follow-up. Secondary outcomes: Mean changes of central macular thickness (CMT) and extension to the fovea. ResultsMean BCVA did not change throughout the follow-up period, being 0.2 ± 0.2 logMAR at baseline and 0.2 ± 0.3 logMAR at the 12-month examination. A functional improvement of at least 2 ETDRS lines was achieved by 5 eyes (33%), with 3 eyes (20%) gaining 3 lines. Mean CMT at baseline was 215 ± 13 μm and 225 ± 85 μm at the 12-month examination. Two eyes (13.3%) showed CNV extension to the fovea. ConclusionsIntravitreal bevacizumab injection can be a beneficial approach for the management of nonsubfoveal CNV secondary to angioid streaks over a 1-year follow-up.

Report this publication

Statistics

Seen <100 times